BioNTech: Oddo BHF raises target price

Published: 2025-06-13 03:49:25 ET BNTX

Published on 06/13/2025 at 03:49

Oddo BHF maintains its "outperform" rating on BioNTech shares, with a target price raised from $130 to $137, following the announcement of a partnership with Bristol-Myers Squibb and the acquisition of CureVac for approximately $1.25bn, in a share exchange. At this stage, the broker is primarily factoring in the partnership with Bristol-Myers Squibb on BNT327, which will enable the German biotech company to secure significant, non-dilutive financing to support its pipeline.According to the analyst, this partnership also allows BioNTech to benefit from BMS's global commercial network and regulatory experience, and to partially divest itself of operational risk while retaining a significant share of future revenues.Oddo BHF also points out that, while it is somewhat surprised by the target, the acquisition of CureVac strengthens BioNTech's position in the field of oncology immunotherapy at a time when CureVac's share price was suffering.Copyright (c) 2025 CercleFinance.com. All rights reserved.The information and analyses published by Cercle Finance are provided solely as a decision-making aid for investors. Cercle Finance cannot be held liable, directly or indirectly, for the use of such information and analyses by its readers. Anyone who is not an expert in the field should consult a professional advisor before investing. This information is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy.